Gender differences in coerced patients with schizophrenia

European Commission (Quality of life and Management of Living Resources Programme, contract number QLG4-CT- 2002-01036), Czech Ministry of Education research grant MSM002160849, and research grants PRVOUK–P26/LF1/4 and PRVOUK–P03/LF1/

The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials

Rationale: The current pharmacotherapy of bipolar depression often presents limited efficacy and increased risk for adverse events. N-acetylcysteine (NAC) has been suggested as potentially effective and well-tolerated adjunctive treatment for bipolar disorder (BD). Objectives: This systematic review and meta-analysis aimed to examine the efficacy of N-acetylcysteine, as an adjunctive therapy, for treating bipolar depression. Methods: PubMed, Cochrane Library, Scopus databases, and grey literature were searched for studies retrieval. Randomized controlled trials including patients with a diagnosed bipolar disorder and a current depressive episode were included in the analysis. The measured variables included symptoms, functioning, and quality of life scales. The mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) was set as the primary outcome. Results: A total of five studies were included in the analysis. A significant improvement was not observed from the addition of NAC to standard therapy in symptomatology [MADRS (MD = −3.32; 95% CI = −12.79 to 6.16), Young Mania Rating Scale (MD = −0.7; 95% CI = −2.15 to 0.75), Bipolar Depression Rating Scale (MD = −3.19; 95% CI = −15.48 to 9.1), and Clinical Global Impression for severity (MD = −0.13; 95% CI = −0.33 to 0.08)], functioning, [Global Assessment of Functioning Scale (MD = 3.21; 95% CI = −12.55 to 18.97), Social and Occupational Functioning Assessment Scale (MD = 0.47; 95% CI = −4.60 to 5.53), or quality of life [Quality of Life Enjoyment and Satisfaction Questionnaire (MD = 2.27; 95% CI = −9.13 to 13.67)]. Conclusions: There is no evidence indicating that NAC has beneficial effects as an adjunctive treatment for bipolar depression. Future trials with improved methodological design and efficient sample sizes are required to draw safer conclusions. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature

Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: impact on caregiver burden

European Congress of Psychiatry (27th. 2019. Warsaw, Poland

Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use

European College of Neuropsychopharmacology, ECNP Congress (31st, 2018, Barcelona, Spain

Symptomatic remission with paliperidone palmitate 3-monthly formulation in schizophrenia patients in a clinical practice setting

Congress of the Schizophrenia International Research Society (2019, Orlando, Florida, USA